Vlastnictví managementu společnosti Aerie Pharmaceuticals Inc
Jaká je hodnota metriky Vlastnictví managementu společnosti Aerie Pharmaceuticals Inc?
Hodnota metriky Vlastnictví managementu společnosti Aerie Pharmaceuticals Inc je 1.79%
Jaká je definice metriky Vlastnictví managementu?
Vlastnictví managementu (Insider Ownership) je poměr akcií vlastněných akcionáři v rámci firmy (akcionáři, kteří vlastní více než 5% společnosti nebo ve funkci ředitele či vedoucího odddělení) a veškerých vydaných akcií.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Vlastnictví managementu společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Aerie Pharmaceuticals Inc
Čemu se věnuje společnost Aerie Pharmaceuticals Inc?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Firmy s metrikou vlastnictví managementu podobnou společnosti Aerie Pharmaceuticals Inc
- Hodnota metriky Vlastnictví managementu společnosti Louisiana-Pacific je 1.79%
- Hodnota metriky Vlastnictví managementu společnosti Amedisys je 1.79%
- Hodnota metriky Vlastnictví managementu společnosti Virtu Inc je 1.79%
- Hodnota metriky Vlastnictví managementu společnosti Palo Alto Networks je 1.79%
- Hodnota metriky Vlastnictví managementu společnosti Palo Alto Networks je 1.79%
- Hodnota metriky Vlastnictví managementu společnosti Middlesex Water Co je 1.79%
- Hodnota metriky Vlastnictví managementu společnosti Aerie Pharmaceuticals Inc je 1.79%
- Hodnota metriky Vlastnictví managementu společnosti Quicklogic Corp je 1.80%
- Hodnota metriky Vlastnictví managementu společnosti Monro Inc je 1.80%
- Hodnota metriky Vlastnictví managementu společnosti Stryker je 1.80%
- Hodnota metriky Vlastnictví managementu společnosti Emcor je 1.80%
- Hodnota metriky Vlastnictví managementu společnosti Ironwood Pharmaceuticals Inc je 1.80%
- Hodnota metriky Vlastnictví managementu společnosti Stinger Resources je 1.80%